A maker of medicines, vaccines, and diagnostics for animals, Zoetis sells well-known products like the dog itch-relief drugs Apoquel and Cytopoint and Simparica parasite preventives to veterinarians worldwide. Born in the 1950s as the animal health arm of Pfizer, it became a fully independent company in 2013. Its name comes from the Greek word "zoe," meaning life—a fitting nod to its mission of keeping animals healthy.
Zoetis reports Q2 2026 revenue flat at $2.5B, net income $691M, and revises FY2026 guidance
Q2 2026 revenue was $2.5 billion, flat versus Q2 2025, with a 1% decline on an organic operational basis.
Show detailsHide details
Reported net income was $691 million, or $1.65 per diluted share, down 5% but up 1% per share year-over-year.
Adjusted net income was $781 million, or $1.87 per diluted share, down 1% on a reported basis and 2% on an organic operational basis.
U.S. segment revenue fell 7% to $1.3 billion, while International segment revenue rose 8% to $1.2 billion.
Full-year 2026 guidance revised to revenue of $9.120-$9.320 billion, adjusted diluted EPS of $6.15-$6.25, and organic operational revenue growth of (3)% to (1)%.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Zoetis appoints James Saccaro as EVP, CFO and COO effective August 17, 2026.
James Saccaro will become Executive Vice President, Chief Financial Officer and Chief Operating Officer effective August 17, 2026, leading global finance and overseeing Global Manufacturing and Supply.
Show detailsHide details
Saccaro previously served as Vice President and CFO of GE HealthCare Technologies Inc. since June 2023 and as EVP and CFO of Baxter International Inc. from 2015 to 2023.
Saccaro's offer letter provides an annual base salary of $1,000,000, target annual incentive of 100% of base salary, target long-term incentive of $5,000,000, and a one-time make-whole RSU award of $6,250,000 plus a $1,250,000 cash award.
Wetteny Joseph will transition from EVP and CFO to a non-executive advisory role after August 16, 2026, serving as Special Advisor to the CEO on financial matters until early 2027.
Joseph's departure is not due to any disagreement with the Company; he will continue to receive his current base salary and benefits until his termination date, with separation benefits under the Executive Severance Plan.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
Leadership8-K
Zoetis director Louise M. Parent retired from the Board effective May 20, 2026.
At the Annual Meeting on May 20, 2026, shareholders elected all twelve director nominees to one-year terms.
Show detailsHide details
Louise M. Parent retired from the Zoetis Inc. Board of Directors effective May 20, 2026, prior to the 2026 Annual Meeting, under the company's director retirement policy.
Shareholders approved, on a non-binding advisory basis, the executive compensation program and voted for an annual frequency of future advisory compensation votes.
Shareholders ratified the appointment of KPMG LLP as independent auditor for fiscal year 2026.
A shareholder proposal to permit action by written consent was not approved.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders
Zoetis reports Q4 and full-year 2025 results; provides 2026 guidance.
Q4 2025 revenue was $2.4 billion, up 3% reported; net income $603 million, or $1.37 diluted EPS, up 4% and 6% respectively.
Show detailsHide details
Full-year 2025 revenue was $9.5 billion, up 2% reported; net income $2.7 billion, or $6.02 diluted EPS, up 8% and 10% respectively.
Q4 2025 adjusted net income was $648 million, or $1.48 adjusted diluted EPS; full-year adjusted net income was $2.8 billion, or $6.41 adjusted diluted EPS.
Net proceeds are estimated at approximately $1.97 billion, with about $186.6 million used for capped call transactions and about $248.0 million to repurchase approximately 2.1 million shares concurrently.
Show detailsHide details
Zoetis issued $2.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2029 in a private placement to qualified institutional buyers.
The remaining approximately $1.535 billion will fund additional share repurchases expected to be completed by the first quarter of 2026.
The notes mature June 15, 2029, bear interest at 0.25% per year, and are convertible at an initial conversion price of approximately $148.20 per share (22.5% premium).
Zoetis entered into capped call transactions with several counterparties to reduce potential dilution, and obtained a waiver under its revolving credit facility to permit early conversions.
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 3.02 Unregistered Sales of Equity Securities · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits